- Home
- SEV vs MCRB Comparison
SEV vs MCRB Comparison
Compare SEV & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEV | MCRB |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | 46 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.2M | 85.7M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SEV | MCRB |
|---|---|---|
| Price | $2.96 | $8.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 238.0K | 37.2K |
| Earning Date | 05-16-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,757.14 | N/A |
| P/E Ratio | ★ N/A | $13.28 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $6.64 |
| 52 Week High | $11.24 | $29.98 |
Technical Indicators
Market Signals| Indicator | SEV | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 37.20 |
| Support Level | $2.37 | $8.08 |
| Resistance Level | $3.26 | $9.53 |
| Average True Range (ATR) | 0.24 | 0.54 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 35.80 | 6.69 |
Price Performance
Historical ComparisonAbout SEV Aptera Motors Corp.
Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.